ADC Analytical Development Summit | May 25-27 2022 | Boston, MA

Memo

As ADCs continue to see clinical success, and as drug design becomes more complex, regulatory scrutiny to ensure product quality is increasing. The trailblazing ADC Analytical Development Summit is the first and only industry focused meeting dedicated to addressing the unique challenges faced by analytical, CMC, QC, process development and protein characterization experts working on ADCs. Covering the end-to-end development and application of analytical technologies in a phase-dependent manner, this novel meeting will focus on enhancing ADC characterization, understanding drug potency and demonstrating homogeneity to support regulatory requirements. With the sharing of unique insights into novel method development, CQAs, bioassays, DAR quantification and distribution, and platform approaches, this is your unmissable opportunity to get up to speed with this rapidly growing field and to support safe, consistent and high quality ADC development. URLs:Tickets: https://go.evvnt.com/989010-1?pid=5569 Brochure: https://go.evvnt.com/989010-3?pid=5569  Date and Time: On Wed, May 25, 2022 ( 9:00 AM) - Fri, May 27, 2022 ( 4:00 PM) Venue details: Hyatt Regency Boston / Cambridge, 575 Memorial Drive, Cambridge, Massachusetts, 02139, United States Prices:Conference + Workshop Day - Drug Developer (on the door): USD 4297.00,Conference Only - Drug Developer (on the door): USD 2999.00,Conference + Workshop Day - Solution Provider (on the door): USD 5097.00,Conference Only - Solution Provider (on the door): USD 3599.00,Conference + Workshop Day - Academics (on the door): USD 3697.00,Conference Only - Academics (on the door): USD 2599.00 Speakers: Mysore Ramprasad Executive Director, Analytical and Formulation Development Ambrx, Shiyue Zhou Senior Scientist II AbbVie, Wayne Yu Senior Scientist, Analytical and Formulation Development Ambrx, Zhen Wu Principal Scientist, Analytical Development ADC Therapeutics, Ashley Mullan Senior Scientist AstraZeneca, Chris Chumase Director, Analytical Development Bristol-Myers Squibb, Patrick Hussman Senior Scientist AstraZeneca, Bolt Biotherapeutics, Chaoran Jing Scientist CytomX, Elizabeth Schmidt Scientific Leader, CMC Analytical GSK, Mark Eggink Principal Scientist Byondis, Simon Letarte Director, Extended Structural Characterization Gilead, Adrienne Wildt Director, Analytical Development ImmunoGen, Hillary Schuessler Director, Mass Spectrometry Merck and Co., Keith Canada Senior Principal Scientist, High Throughput Materials and Biophysical Characterization Merck and Co., Susan Clardy Associate Director, Analytical CMC Mersana Therapeutics, Annika Yau Senior Scientist, Discovery Analytical Chemistry Mersana Therapeutics, Romesh Rao Scientist Seagen